Sareum allowed European patent for primary kinase inhibitor asset

The AIM-traded firm said the patent application reinforced the protection of SDC‐1801, particularly in its medical applications for autoimmune disease treatment and specific synthesis methods.

It noted that the approval followed similar nods from the China National Intellectual Property Administration and the Japan Patent Office last year, solidifying the intellectual property protection of SDC‐1801 in key global markets.

While patent applications in the United States and other territories still under review, Sareum said it expected the prompt grant of the patent pending completion of formalities.

“This new patent allows us to enhance our intellectual property portfolio in a crucial market,” said chief scientific officer Dr John Reader.

“Our phase 1a trial for SDC-1801 in Australia is progressing smoothly, with the single ascending dose and food effect study revealing no significant adverse events.

“This progress highlights the potential of SDC-1801 to achieve therapeutic drug levels in the bloodstream through once-daily oral dosing.”

At 1229 GMT, shares in Sareum Holdings were down 2.08% at 23.5p.

Reporting by Josh White for Sharecast.com.